Donanemab may offer new hope for people with early Alzheimer’s disease

FHS
July 17, 2023
5:44 pm

The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer’s disease demonstrate an important advancement in Alzheimer’s research and treatment.

Gilead and MSD to advance once-weekly HIV treatment to Phase III – Pharmaceutical Technology

The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to

October 22, 2024

#ASH24: Arcellx and Gilead seek to unseat Legend and J&J with multiple myeloma cell therapy

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 10, 2024

What if Medicaid Enrollees Were Given Cash Instead of Insurance Benefits?

Everything old is new again. Back in 1989, U.S. conservatives were promoting an approach to Medicare known as “defined contribution,” under which — instead of

May 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.